Home Uncategorized

Uncategorized

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book ‘The Nature of Drugs’

Henrik Dahl’s Review of Pickard’s ‘The Rose of Paracelsus: On Secrets and Sacraments’

Why The Future of The Psychedelic Industry Could Be In The Hands of Retail Investors

Psychedelic Guides with Ketan Patel of Next Healthcare Technologies Inc

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

atai Life Sciences Increases its Ownership Position in COMPASS Pathways

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

A New Path To Wealth: Navigating The Psychedelic Investment Landscape

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet...

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

PsyCap Recap: 3 Key Takeaways From the Shroom Bloom Psychedelic Capital...

Markets for Feb 26: $AION +8.33%, $CYBN -19.19%, $FTRP -13.09%

Psychedelics Versus Cannabis: Exploring their Impact on Treating Mental Illness

Markets for Feb 17: EHVVF +17.85%, MSET +15.04%, NM +8.93%

February’s Psychedelic Capital Investigates Institutional Vs Retail Investor Impact

12 3...13 Page 1 of 13

The Backyard Psychedelic Renaissance: How Bottom-Up Change Is Delivering Psychedelic Access

Dreamshadow Transpersonal Breathwork

Statement Regarding The Church of the Sacred Synthesis

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.